Guidelines for managing high blood pressure

JAMA

Volumn 312, Issue 3, 2014, Pages 293-294

  Morales Salinas, Alberto ^a   Coca, Antonio ^b   Wyss, Fernando Stuardo ^c  

^a Hospital Universitario Cardiocentro Ernesto Guevara   (Cuba)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Hospital General San Juan de Dios Guatemala   (Guatemala)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CARVEDILOL; NEBIVOLOL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LETTER; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION;

EID: 84904262594     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.6590     Document Type: Letter

References (5)

1. Bangalore S, Steg G, Deedwania P, et al REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349.
2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
3. Dahlöf B, Devereux RB, Kjeldsen SE, et al LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. (Pubitemid 34286536)
4. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: ameta-analysis. CMAJ. 2006;174(12):1737-1742. (Pubitemid 43893565)
5. McGill JB. Optimal use of β-blockers in high-risk hypertension: a guide to dosing equivalence. Vasc Health Risk Manag. 2010;6:363-372.